Longenesis has announced that a study on Type 1 diabetes care, undertaken in partnership with Medtronic, has demonstrated that insulin pump use supports a higher quality of life.
Across less than three months, more than 85 patients participated in the research study aimed at providing qualitative and quantitative data on the quality of life for Type 1 diabetics using insulin pumps compared to daily insulin injections.
Approximately 80% of patients in the study reviewed their participation as satisfactory, with no patients expressing dissatisfaction, according to Longenesis, with cost being the main reason given for stopping insulin pump usage, emphasising the importance of patient-centric reimbursement policies for diabetes patients.
The project findings may serve as a tool for patient advocacy groups and respective stakeholders in drawing their government’s attention to the needs of Type 1 diabetes patients in managing their care, both financially and personally.
To read more, CLICK HERE.